The introduction of long-acting antiviral prophylaxis drugs, exemplified by the twice-yearly injectable capsid inhibitor lenacapavir 1,2, marks a remarkable advance in HIV prevention, which address the adherence issue that has limited the real-world use of daily oral pre-exposure prophylaxis (PrEP) 3,4. The long-acting formulations of lenacapavir offer a potent prevention tool, particularly well-suited for countries where the HIV transmission mainly occurred in certain populations with high incidence.
Sun et al. (Tue,) studied this question.